Michael V Ortiz

Trials

Studies that name Michael V Ortiz as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:12 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT06620302 · Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

  Children's Oncology Group · suspended · Childhood Fibrolamellar Carcinoma, Recurrent Childhood Fibrolamellar Carcinoma, Recurrent Childhood Malignant Solid Neoplasm · principal investigator
• Ph1/Ph2
  NCT05071209 · Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

  National Cancer Institute (NCI) · active not recruiting · Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 13:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Pediatric Early Phase Clinical Trials Network (PEP-CTN) Transfer Application
  UM1CA228823 · NCI · COG RESEARCH FOUNDATION, LLC · PI Elizabeth Fox · fiscal years 2018 to 2026
  Named on NCT06620302, NCT05071209